Yale Cancer Center - Concepedia

Concepedia

Institution (Facility)

Yale Cancer Center

Homepage Wikipedia ROR

Also Known As

Yale Cancer Center, Yale Cancer Ctr, Yale Comprehensive Cancer Center, Yale-New Haven Cancer Center · Acronym: YCC

10.7K

Publications

1.2M

Citations

452

Authors

1.5K

Concepts

About

Yale Cancer Center is a facility institution in New Haven, United States known for medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	73	759	65.6K
2	Engineering	46	347	34.9K
3	Education	19	59	8.2K
4	Business	8	14	1.6K
5	Arts	7	8	287

Yale Cancer Center

×

10.7K

Publications

1.2M

Citations

	Year	Citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, New England Journal of Medicine	2012	12.5K
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer H. Borghaei, L. Paz-Ares, Leora Horn, New England Journal of Medicine	2015	9.3K
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2015	8K
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Roy S. Herbst, Paul Baas, Dong‐Wan Kim, The Lancet Pembrolizumab Versus DocetaxelOncologyClinical TrialsImmune Checkpoint InhibitorPharmacotherapy	2015	6.4K
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Nature MedicineBiomarker TargetAnti-pd-l1 Antibody Mpdl3280aImmunologyPathology	2014	5.2K
How We Design Feasibility Studies Deborah J. Bowen, Matthew W. Kreuter, Bonnie Spring, American Journal of Preventive Medicine Requirement AnalysisProject ManagementDesignDesign ThinkingBusiness Case	2009	3.5K
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Barbara Burtness, Kevin J. Harrington, Richard Greil, The Lancet Neoadjuvant TherapyChemotherapy Versus CetuximabMedicinePathologyHead And Neck Cancer	2019	3K
Pembrolizumab for Early Triple-Negative Breast Cancer Peter Schmid, Javier Cortés, Lajos Pusztai, New England Journal of Medicine	2020	2.9K
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid Oscar R. Colegio, Ngoc-Quynh Chu, Alison L. Szabo, Nature InflammationLacrimal GlandImmunologyFunctional PolarizationTumor Targeting	2014	2.8K
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, The Lancet Oncology Checkmate 037MedicineMelanomaNivolumab Versus ChemotherapyImmune Checkpoint Inhibitor	2015	2.6K

Page 1